At the EBMT 2025 annual meeting, Dr. Kirill Kirgizov presented findings from a comprehensive retrospective survey (GS2-10) on late complications following autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases (AD). Conducted by the EBMT Autoimmune Diseases and Transplant Complications Working Parties, this study sheds light on an often underexplored aspect of survivorship care.
The analysis revealed a significant cumulative burden of non-infectious late complications in these patients including thyroid dysfunction, osteoporosis, cardiac and gonadal dysfunction, secondary autoimmune diseases, and even subsequent malignancies. Importantly, the study emphasized that the type and frequency of these complications vary by disease.
Dr. Kirgizov underscored the urgent need for standardized post-HSCT monitoring protocols. Routine screening, proactive management, and early intervention are essential to mitigate these risks and improve long-term outcomes. The findings advocate for harmonized guidelines to support physicians in managing the long-term care of patients who undergo auto-HSCT for autoimmune indications.
Thank you, Dr. Kirgizov, for this crucial contribution to the field.
